Cargando…

Baricitinib induces LDL-C and HDL-C increases in rheumatoid arthritis: a meta-analysis of randomized controlled trials

BACKGROUND: Baricitinib, an oral-administrated selective inhibitor of the JAK1 and JAK2, is recently approved for rheumatoid arthritis (RA) treatment. With the aim to provide some insights on the clinical safety, the current study mainly focused on the effect of baricitinib on low-density lipoprotei...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qiu, Chengfeng, Zhao, Xiang, She, Lang, Shi, Zhihua, Deng, Ziwei, Tan, Liming, Tu, Xiaojun, Jiang, Shilong, Tang, Bin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380020/ https://www.ncbi.nlm.nih.gov/pubmed/30777075 http://dx.doi.org/10.1186/s12944-019-0994-7

Ejemplares similares

Baricitinib for the treatment of rheumatoid arthritis
por: Urits, Ivan, et al.
Publicado: (2020)

Effect of Tocilizumab on LDL and HDL Characteristics in Patients with Rheumatoid Arthritis. An Observational Study
por: Pierini, Florencia S., et al.
Publicado: (2021)

LDL-C/HDL-C Ratio Predicts Carotid Intima-Media Thickness Progression Better Than HDL-C or LDL-C Alone
por: Enomoto, Mika, et al.
Publicado: (2011)

Trends in LDL-C and Non-HDL-C Levels with Age
por: Zhang, Peng, et al.
Publicado: (2020)

Implication of Low HDL-c Levels in Patients with Average LDL-c Levels: A Focus on Oxidized LDL, Large HDL Subpopulation, and Adiponectin
por: Mascarenhas-Melo, Filipa, et al.
Publicado: (2013)

Oxidative modifications of foetal LDL-c and HDL-c lipoproteins in preeclampsia
por: León-Reyes, G., et al.
Publicado: (2018)

Baricitinib exposure during pregnancy in rheumatoid arthritis
por: Costanzo, Giulia, et al.
Publicado: (2020)

Role of Lipid Profile and Its Relative Ratios (Cholesterol/HDL-C, Triglyceride/HDL-C, LDL-C/HDL-C, WBC/HDL-C, and FBG/HDL-C) on Admission Predicts In-Hospital Mortality COVID-19
por: Mohammadshahi, Jafar, et al.
Publicado: (2023)

Which one of LDL-C /HDL-C ratio and non-HDL-C can better predict the severity of coronary artery disease in STEMI patients
por: Gao, Po, et al.
Publicado: (2022)

A high LDL-C to HDL-C ratio predicts poor prognosis for initially metastatic colorectal cancer patients with elevations in LDL-C
por: Liao, Fangxin, et al.
Publicado: (2015)

Serum LDL-C/HDL-C ratio and the risk of carotid plaques: a longitudinal study
por: Wu, Zhuchao, et al.
Publicado: (2022)

Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis
por: Fleischmann, Roy, et al.
Publicado: (2017)

Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis
por: Taylor, Peter C., et al.
Publicado: (2019)

Homogeneous Assays for LDL-C and HDL-C are Reliable in Both the Postprandial and Fasting State
por: Miida, Takashi, et al.
Publicado: (2017)

New alternative in the treatment of rheumatoid arthritis: clinical utility of baricitinib
por: Kawalec, Paweł, et al.
Publicado: (2019)

Are There Any Ethnic Differences in the Response to Baricitinib for the Treatment of Rheumatoid Arthritis?
por: Zahir Hussain, Wajith Hussain, et al.
Publicado: (2021)

A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience
por: Taylor, Peter C., et al.
Publicado: (2023)

Emergent Biomarkers of Residual Cardiovascular Risk in Patients with Low HDL-c and/or High Triglycerides and Average LDL-c Concentrations: Focus on HDL Subpopulations, Oxidized LDL, Adiponectin, and Uric Acid
por: Mascarenhas-Melo, Filipa, et al.
Publicado: (2013)

Combining LDL-C and HDL-C to predict survival in late life: The InChianti study
por: Zuliani, Giovanni, et al.
Publicado: (2017)

Friedewald formula may be used to calculate non-HDL-C from LDL-C and TG
por: Romaszko, Jerzy, et al.
Publicado: (2023)

LDL-C/HDL-C is associated with ischaemic stroke in patients with non-valvular atrial fibrillation: a case-control study
por: Zhang, Xiao-Xue, et al.
Publicado: (2020)

Palmoplantar Pustulosis-like Eruption Induced by Baricitinib for Treatment of Rheumatoid Arthritis
por: Koumaki, Dimitra, et al.
Publicado: (2019)

Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis
por: Harigai, Masayoshi, et al.
Publicado: (2020)

Association between LDL-C, Non HDL-C, and Apolipoprotein B Levels with Coronary Plaque Regression
por: Masson, Walter, et al.
Publicado: (2015)

Is evaluation of non-HDL-C better than calculated LDL-C in CAD patients? MMIMSR experiences
por: Kathariya, Gobardhan, et al.
Publicado: (2020)

LDL-C, NON-HDL-C and APO-B for cardiovascular risk assessment: Looking for the ideal marker
por: Aggarwal, Dr Jyoti, et al.
Publicado: (2021)

HDL-C/LDL-C and Risk of Cerebral White Matter Hyperintensities: A Cross-Sectional Study
por: Wei, Cunsheng, et al.
Publicado: (2023)

Non-HDL-C Is More Stable Than LDL-C in Assessing the Percent Attainment of Non-fasting Lipid for Coronary Heart Disease Patients
por: Guo, Li-Ling, et al.
Publicado: (2021)

Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis
por: Genovese, Mark C, et al.
Publicado: (2018)

Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis
por: Iwamoto, Naoki, et al.
Publicado: (2021)

Effectiveness of Baricitinib in Refractory Seronegative Rheumatoid Arthritis and Uveitis: A Case Report
por: Kaneko, Yutaka, et al.
Publicado: (2022)

Systematic Literature Review of Real-World Evidence on Baricitinib for the Treatment of Rheumatoid Arthritis
por: Hernández-Cruz, Blanca, et al.
Publicado: (2023)

Associação Positiva entre Autoanticorpos contra LDL Oxidada e HDL-C: Um Novo Mecanismo para Cardioproteção de HDL?
por: Nunez, Carla Evelyn Coimbra, et al.
Publicado: (2022)

High levels of LDL-C combined with low levels of HDL-C further increase platelet activation in hypercholesterolemic patients
por: Chan, L.W., et al.
Publicado: (2014)

Caryocar brasiliense Cambess. Pulp Oil Supplementation Reduces Total Cholesterol, LDL-c, and Non-HDL-c in Animals
por: Torres Silva, Gabriela, et al.
Publicado: (2020)

Characterization and Changes of Lymphocyte Subsets in Baricitinib‐Treated Patients With Rheumatoid Arthritis: An Integrated Analysis
por: Tanaka, Yoshiya, et al.
Publicado: (2018)

Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2020)

Baricitinib therapy response in rheumatoid arthritis patients associates to STAT1 phosphorylation in monocytes
por: Tucci, Gloria, et al.
Publicado: (2022)

Difficult-to-treat rheumatoid arthritis treated with Abatacept combined with Baricitinib: A case report
por: Qi, Jia-Ping, et al.
Publicado: (2023)

Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib
por: Harrington, Robert, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bh8n13ofu2o83el74g8bhgs8d7